Skip to main navigation Skip to search Skip to main content

A Multicenter, Long-Term Extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Alzheimer’s Disease

  • O'Brien, Terence (Primary Chief Investigator (PCI))
  • Stewart, Natasha (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date2/05/23 → 2/05/25

Keywords

  • clinical trial
  • Alzheimer’s
  • monoclonal IgG1 antibody
  • AL002
  • myeloid cells

Clinical Trial Phase

  • Phase II